Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $9.43 Consensus Price Target from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTAGet Free Report) has been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.43.

Several analysts recently commented on the company. Morgan Stanley raised Centessa Pharmaceuticals from an “underweight” rating to an “equal weight” rating and raised their target price for the stock from $4.00 to $8.00 in a report on Thursday, October 26th. Jefferies Financial Group upgraded Centessa Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $4.00 to $11.00 in a research report on Wednesday, November 15th.

Read Our Latest Stock Report on Centessa Pharmaceuticals

Insider Activity

In other news, SVP Harris Rotman sold 4,267 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.10, for a total value of $34,562.70. Following the completion of the sale, the senior vice president now directly owns 62,625 shares of the company’s stock, valued at approximately $507,262.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.54% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. increased its position in Centessa Pharmaceuticals by 25.8% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock valued at $18,313,000 after acquiring an additional 580,500 shares during the period. Point72 Asset Management L.P. increased its position in Centessa Pharmaceuticals by 13.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,011,388 shares of the company’s stock valued at $12,450,000 after acquiring an additional 235,906 shares during the period. Affinity Asset Advisors LLC increased its position in Centessa Pharmaceuticals by 13.0% in the 3rd quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock valued at $6,587,000 after acquiring an additional 117,368 shares during the period. Woodline Partners LP increased its position in Centessa Pharmaceuticals by 10.2% in the 1st quarter. Woodline Partners LP now owns 882,633 shares of the company’s stock valued at $7,917,000 after acquiring an additional 81,497 shares during the period. Finally, Platinum Investment Management Ltd. increased its position in Centessa Pharmaceuticals by 96.7% in the 3rd quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company’s stock valued at $2,184,000 after acquiring an additional 165,919 shares during the period. Institutional investors and hedge funds own 73.92% of the company’s stock.

Centessa Pharmaceuticals Trading Down 6.8 %

Shares of NASDAQ:CNTA opened at $7.57 on Monday. The business’s 50-day moving average is $7.48 and its 200 day moving average is $6.94. Centessa Pharmaceuticals has a 1 year low of $3.00 and a 1 year high of $8.90. The firm has a market capitalization of $739.06 million, a P/E ratio of -4.62 and a beta of 1.24. The company has a debt-to-equity ratio of 0.29, a current ratio of 9.51 and a quick ratio of 9.51.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Free Report) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. On average, research analysts predict that Centessa Pharmaceuticals will post -1.63 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

(Get Free Report

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

Read More

Analyst Recommendations for Centessa Pharmaceuticals (NASDAQ:CNTA)

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.